Curis : FDA Clears IND Application For Monoclonal Anti-VISTA Antibody CI-8993

By RTTNews Staff Writer ✉ | Published: 6/10/2020 8:08 AM ET

Curis Inc. (CRIS) said Wednesday that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Curis plans to initiate a Phase 1a/1b study of CI-8993 in the second half of 2020.

Certain cancers, such as mesothelioma, triple negative breast cancer, non-small cell lung cancer, and gynecologic malignancies, are known to be highly driven by VISTA. These cancers may be amenable to monotherapy treatment with anti-VISTA therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks PDUFA COVID 19 Vaccines peanut allergy Trelegy Ellipta Pain drug exertional heatstroke allergic conjunctivitis

Biotech Stocks Facing FDA Decision In August 2020

New Drugs Approved In June

Coronavirus Vaccines In Human Trials COVID19 Antibodies Spike Protein US Operation Warp Speed

Tracking Coronavirus Vaccines In Human Trials

Editors Pick

Facebook Releases Instagram Reels

Facebook has unveiled Instagram Reels as its answer to the popular Chinese-owned video app TikTok. The social media giant said in a blog post that Instagram Reels is a new way to create short, entertaining videos on Facebook's photo-sharing app Instagram. Facebook reportedly shut down its TikTok clone Lasso in July, ahead of the launch of Instagram Reels.

WD-40 Company Recalls About 130k Units Of X-14 Mildew Stain Remover

WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation.

Bristol-Myers Slips To Loss In Q2, But Results Top Estimates

Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020.